Venture capital expert Dr. Niclas von Woedtke to join HEUKING

Effective May 1, 2026, Dr. Niclas v. Woedtke, MBA (45), will join HEUKING as an Equity Partner at the Hamburg office. He will further strengthen the firm’s Venture Capital/M&A and Health Care & Life Sciences practices.

Niclas v. Woedtke joins from Taylor Wessing, where he advised on Corporate/M&A and established himself as a leading practitioner in venture capital transactions in the biotech sector. Prior to that, he worked at Boehringer Ingelheim and Otto Group.

His practice focuses on advising growth companies, with particular emphasis on spin-offs from corporates and universities in technology-driven and research- intensive fields. He also advises venture capital and venture debt investors on equity and debt investments throughout the entire company life cycle, including exits, and offers corporate and transactional advice to clients in the life sciences and healthcare sectors.

“Niclas von Woedtke is an excellent addition to our teams advising growth companies and venture capital investors. With his strong industry expertise in life sciences, he offers significant potential for new mandates and cross-practice collaboration,” said Dr. Michael Dröge, Partner at HEUKING’s Hamburg office. Boris Dürr, Managing Partner at HEUKING, added: “We are gaining an experienced colleague whose profile will further strengthen our existing capabilities, and we very much look forward to working with him. Niclas von Woedtke will be based in Hamburg and will also work extensively from Munich, jointly with his former and, now again new, colleagues from our Life Sciences team.”

In September 2025, a team of three female Equity Partners from Taylor Wessing in Munich, with whom von Woedtke had previously worked closely, joined HEUKING’s Health Care & Life Sciences practice. This collaboration will now be continued and further expanded at HEUKING.